The stock of Cytokinetics, Inc. (NASDAQ:CYTK) is a huge mover today! The stock increased 4.42% or $0.5 on November 23, hitting $11.8. About 361,676 shares traded hands or 15.19% up from the average. Cytokinetics, Inc. (NASDAQ:CYTK) has risen 38.34% since April 22, 2016 and is uptrending. It has outperformed by 32.93% the S&P500.
The move comes after 7 months positive chart setup for the $480.22 million company. It was reported on Nov, 24 by Barchart.com. We have $12.15 PT which if reached, will make NASDAQ:CYTK worth $14.41 million more.
Analysts await Cytokinetics, Inc. (NASDAQ:CYTK) to report earnings on February, 21. They expect $-0.33 earnings per share, down 37.50% or $0.09 from last year’s $-0.24 per share. After $0.74 actual earnings per share reported by Cytokinetics, Inc. for the previous quarter, Wall Street now forecasts -144.59% negative EPS growth.
Cytokinetics, Inc. (NASDAQ:CYTK) Ratings Coverage
Out of 6 analysts covering Cytokinetics (NASDAQ:CYTK), 6 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Cytokinetics has been the topic of 6 analyst reports since July 24, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating given on Friday, July 24 by MLV. The company was maintained on Monday, November 9 by TH Capital. The company was maintained on Tuesday, November 10 by FBR Capital. JMP Securities maintained the shares of CYTK in a report on Wednesday, March 9 with “Market Outperform” rating. The rating was maintained by Needham on Wednesday, July 27 with “Buy”. The company was maintained on Monday, November 9 by Roth Capital.
According to Zacks Investment Research, “Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology and mechanics of muscle performance, the company is developing small molecule drug candidates engineered to increase muscle function and contractility. Cytokinetics’ lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the FDA and orphan medicinal product designation by the EMA. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure, and with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy.”
Insitutional Activity: The institutional sentiment increased to 1.16 in 2016 Q2. Its up 0.70, from 0.46 in 2016Q1. The ratio is positive, as 19 funds sold all Cytokinetics, Inc. shares owned while 37 reduced positions. 8 funds bought stakes while 18 increased positions. They now own 26.30 million shares or 0.76% less from 26.50 million shares in 2016Q1.
Credit Suisse Ag owns 22,839 shares or 0% of their US portfolio. Blackrock Gru accumulated 0% or 11,656 shares. The Massachusetts-based Rhumbline Advisers has invested 0% in Cytokinetics, Inc. (NASDAQ:CYTK). Wasatch Advisors Inc owns 1.75 million shares or 0.25% of their US portfolio. Wellington Grp Incorporated Llp has 1.81 million shares for 0% of their US portfolio. The Massachusetts-based Wade G W And has invested 0.03% in Cytokinetics, Inc. (NASDAQ:CYTK). Pnc Financial Services Group has 221,522 shares for 0% of their US portfolio. Jacobs Levy Equity Management Inc accumulated 22,130 shares or 0% of the stock. California Pub Employees Retirement Systems owns 82,675 shares or 0% of their US portfolio. Cornerstone Cap Mgmt Holdings Ltd owns 8,600 shares or 0% of their US portfolio. Stoneridge Ptnrs Ltd Company accumulated 0.02% or 15,655 shares. Keybank Association Oh holds 44,168 shares or 0% of its portfolio. Moreover, Citigroup has 0.01% invested in Cytokinetics, Inc. (NASDAQ:CYTK) for 711,819 shares. Globeflex Cap Limited Partnership, a California-based fund reported 83 shares. Moreover, Manufacturers Life Commerce The has 0% invested in Cytokinetics, Inc. (NASDAQ:CYTK) for 25,695 shares.
More important recent Cytokinetics, Inc. (NASDAQ:CYTK) news were published by: Fool.com which released: “Why Cytokinetics, Inc. Got Hammered Today” on September 01, 2016, also Marketwatch.com published article titled: “/quotes/zigman/3870025/realtime”, Globenewswire.com published: “Cytokinetics, Inc. Reports Third Quarter 2016 Financial Results” on October 27, 2016. More interesting news about Cytokinetics, Inc. (NASDAQ:CYTK) was released by: Globenewswire.com and their article: “Cytokinetics, Inc. Reports Second Quarter 2016 Financial Results” with publication date: July 28, 2016.
CYTK Company Profile
Cytokinetics, Incorporated, incorporated on August 5, 1997, is a late-stage biopharmaceutical company. The Firm is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. The Firm is developing small molecule drug candidates, which are specifically engineered to increase muscle function and contractility. The Company’s drug candidates, which are in clinical development include tirasemtiv, CK-2127107 and omecamtiv mecarbil.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.